Edition:
United States

Coloplast A/S (COLOb.CO)

COLOb.CO on Copenhagen Stock Exchange

625.60DKK
10:59am EST
Change (% chg)

kr.-7.40 (-1.17%)
Prev Close
kr.633.00
Open
kr.633.00
Day's High
kr.638.00
Day's Low
kr.620.20
Volume
260,370
Avg. Vol
297,755
52-wk High
kr.716.60
52-wk Low
kr.474.30

Latest Key Developments (Source: Significant Developments)

Coloplast Board Has Elected Lars Søren Rasmussen As Chairman
Wednesday, 5 Dec 2018 11:39am EST 

Dec 5 (Reuters) - Coloplast A/S ::BOARD HAS ELECTED LARS SØREN RASMUSSEN AS CHAIRMAN AND NIELS PETER LOUIS-HANSEN AS DEPUTY CHAIRMAN.  Full Article

Coloplast Q4 EBIT At DKK 1.42 Billion, Below Consensus
Thursday, 1 Nov 2018 07:31am EDT 

Nov 1 (Reuters) - Coloplast A/S ::REG-ANNOUNCEMENT NO. 9/2018 - FULL-YEAR FINANCIAL RESULTS 2017/18.Q4 ORGANIC GROWTH WAS 8%, WHILE REVENUE IN DKK INCREASED BY 6% TO DKK 4,234M..RECOMMENDS THAT SHAREHOLDERS APPROVE YEAR-END DIVIDEND OF DKK 11.00 PER SHARE.Q4 REVENUE DKK 4.23 BILLION (REUTERS POLL DKK 4.39 BILLION).GUIDANCE 2018/19: ORGANIC REVENUE GROWTH OF ABOUT 8% AT CONSTANT EXCHANGE RATES. REPORTED GROWTH IN DKK IS GUIDANCE AT 8-9.Q4 EBIT DKK 1.42 BILLION (REUTERS POLL DKK 1.45 BILLION).2018/19 CAPITAL EXPENDITURE IS EXPECTED TO BE ABOUT DKK 750M, AND EFFECTIVE TAX RATE IS EXPECTED TO BE ABOUT 23%.Q4 PRETAX PROFIT DKK 1.36 BILLION (REUTERS POLL DKK 1.44 BILLION).EXPECT AN 2018/19 EBIT MARGIN OF 30-31% AT CONSTANT EXCHANGE RATES AND A REPORTED EBIT MARGIN OF ABOUT 31% IN DKK.  Full Article

Coloplast: Lars Rasmussen Steps Down As CEO
Thursday, 1 Nov 2018 07:28am EDT 

Nov 1 (Reuters) - Coloplast A/S ::REG-ANNOUNCEMENT NO. 8/2018 - LARS RASMUSSEN STEPS DOWN AS CEO OF COLOPLAST A/S.REG-ANNOUNCEMENT NO. 8/2018 - LARS RASMUSSEN STEPS DOWN AS CEO OF COLOPLAST A/S.APPOINTS KRISTIAN VILLUMSEN AS NEW CEO.LARS RASMUSSEN HAS BEEN NOMINATED BY BOARD OF DIRECTORS TO ASSUME ROLE OF CHAIRMAN OF BOARD OF DIRECTORS.CEO, LARS RASMUSSEN HAS DECIDED TO STEP DOWN AS CEO OF COLOPLAST A/S AS OF DECEMBER 4(TH), 2018.BOARD OF DIRECTORS HAS APPOINTED KRISTIAN VILLUMSEN, CURRENTLY EXECUTIVE VICE PRESIDENT, CHRONIC CARE, AS NEW CEO AS OF DECEMBER 4(TH), 2018.MICHAEL PRAM RASMUSSEN WILL NOT STAND FOR RE-ELECTION AT NEXT ANNUAL GENERAL MEETING.PROCESS TO FIND A SUCCESSOR FOR KRISTIAN VILLUMSEN HAS BEEN INITIATED.  Full Article

Coloplast Launches Share Buy-Back Programme
Tuesday, 20 Feb 2018 04:44am EST 

Feb 20 (Reuters) - COLOPLAST ::REG-ANNOUNCEMENT NO. 3/2018 - SHARE BUYBACK PROGRAMME.IS LAUNCHING A SHARE BUY-BACK PROGRAMME OF UP TO DKK 1BN..‍FIRST PART OF PROGRAMME, OF DKK 500M, EXPECTED TO TAKE PLACE DURING PERIOD FROM 26 FEB 2018 TO 25 AUG 2018​.SECOND PART OF DKK 500M IS EXPECTED TO COMMENCE IN Q2 2018/19 AND BE COMPLETED BEFORE FINANCIAL YEAR END 2018/19.  Full Article

Coloplast Acquires IncoCare in Germany
Wednesday, 7 Feb 2018 06:31am EST 

Feb 7 (Reuters) - Coloplast A/S ::REG-COLOPLAST ACQUIRES INCOCARE GUNHILD VIELER GMBH.COLOPLAST - PURCHASE PRICE IS UNDISCLOSED..COLOPLAST - TRANSACTION WILL NOT IMPACT COLOPLAST'S FINANCIAL GUIDANCE FOR 17/18..  Full Article

Coloplast CFO Says Greek Authorities Have Reduced Prices In Our Segments By Around 25 Percent Final Price Settlement Due After Appeal Period
Thursday, 1 Feb 2018 08:13am EST 

Feb 1 (Reuters) - COLOPLAST CHIEF FINANCIAL OFFICER ANDERS LONNING-SKOVGAARD SAYS IN TELEPHONE INTERVIEW::GREEK AUTHORITIES HAVE REDUCED PRICES IN OUR SEGMENTS BY AROUND 25 PERCENT.FINAL PRICE SETTLEMENT IN GREECE DUE AFTER APPEAL PERIOD.  Full Article

Coloplast Q1 EBIT Below Expectations At DKK 1.21 Billion
Thursday, 1 Feb 2018 06:01am EST 

Feb 1 (Reuters) - COLOPLAST ::REG-ANNOUNCEMENT NO. 02/2018 - Q1 INTERIM FINANCIAL REPORT, 2017/18.Q1 REPORTED REVENUE IN DKK WAS UP BY 5% TO DKK 3,955M.‍CONTINUES TO EXPECT 2017/18 ORGANIC REVENUE GROWTH OF 7% AT CONSTANT EXCHANGE RATES​.Q1 EBIT DKK 1.21 BILLION (REUTERS POLL DKK 1.25 BILLION).Q1 REVENUE DKK 3.96‍​ BILLION (REUTERS POLL DKK 3.98 BILLION).Q1 PRETAX PROFIT DKK 1.22 BILLION (REUTERS POLL DKK 1.25 BILLION).  Full Article

Coloplast Acquires SAS Lilial
Monday, 18 Dec 2017 09:28am EST 

Dec 18 (Reuters) - Coloplast ::ANNOUNCEMENT NO. 13/2017 - COLOPLAST A/S ACQUIRES SAS LILIAL.TO ACQUIRE SAS LILIAL FOR A CASH CONSIDERATION OF EUR 35.5M EQUAL TO APPROX. DKK 264M ON A CASH AND DEBT-FREE BASIS​.‍TRANSACTION IS SUBJECT TO CUSTOMARY CLOSING CONDITIONS, AND IS EXPECTED TO CLOSE BEFORE YEAR-END 2017​.‍ACQUISITION WILL, IF COMPLETED, LEAD TO A REVISED FINANCIAL GUIDANCE FOR FINANCIAL YEAR 2017/18​.‍LILIAL IS EXPECTED TO RECORD SALES OF APPROX. EUR 33M OR APPROX. DKK 246M FOR FULL-YEAR 2017​.  Full Article

Coloplast CFO Buys 18,693 Shares In Company For Dkk 5,448,261.78‍​
Monday, 11 Dec 2017 05:26am EST 

Dec 11 (Reuters) - Coloplast ::CFO BUYS 18,693 SHARES IN COMPANY FOR DKK 5,448,261.78‍​.  Full Article

Coloplast sees 2017/2018 revenue growth at lower end of long-term outlook
Thursday, 2 Nov 2017 07:09am EDT 

Nov 2 (Reuters) - COLOPLAST :Q4 REVENUE DKK 3.98‍​ BILLION (REUTERS POLL DKK 4.02 BILLION).Q4 PRETAX PROFIT DKK ‍​1.33 BILLION (REUTERS POLL DKK 1.34 BILLION).‍EXPECT ORGANIC REVENUE GROWTH OF C7% AT CONSTANT EXCHANGE RATES.Q4 EBIT DKK ‍​1.32 BILLION (REUTERS POLL DKK 1.32 BILLION).‍EXPECTS IN 2017/2018 AN EBIT MARGIN OF 31-32% AT CONSTANT EXCHANGE RATES​.‍IN 2017/2018 CAPITAL EXPENDITURE IS EXPECTED TO BE ABOUT DKK 700M AND EFFECTIVE TAX RATE IS EXPECTED TO BE ABOUT 23%​.‍RECOMMENDS TO APPROVE A YEAR-END DIVIDEND OF DKK 10.5 PER SHARE.​.‍INTENDS TO PURSUE INORGANIC GROWTH OPPORTUNITIES TO FURTHER STRENGTHEN ITS SERVICE OFFERING TO CONSUMER​.COLOPLAST - LONG-TERM ‍ORGANIC REVENUE GROWTH GUIDANCE IS MAINTAINED AT 7-9% P.A. WHERE AMBITION IS TO REACH UPPER END OF INTERVAL​.COLOPLAST - LONG-TERM, ‍EBIT MARGIN GUIDANCE REVISED FROM 50-100BP IMPROVEMENT P.A., TO EBIT MARGIN OF >30% AT CONSTANT CURRENCIES​.  Full Article